Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01680900 · ClinicalTrials.gov registry record · NA
Vilazodone for Menopausal Hot Flashes
A NA study of Hot Flushes, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01680900 is a NA study of Hot Flushes that has completed, run by University of Pennsylvania. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01680900, a NA study of Hot Flushes, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.
Conditions Studied
Interventions
- DRUG vilazodone
- DRUG placebo capsules
Study Locations (1)
Pennsylvania
- Dept OB/GYN, Mudd Professorship Suite - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01680900
The ClinicalTrials.gov registry entry for NCT01680900 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hot Flushes appearing as the primary indexed condition, and to 2 interventions - of which vilazodone is the first listed.
NCT01680900 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01680900 about?
NCT01680900 is a clinical study titled "Vilazodone for Menopausal Hot Flashes". This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.
What is the current status of trial NCT01680900?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2013-08.
What conditions does trial NCT01680900 study?
This clinical trial studies the following conditions: Hot Flushes.
What interventions are being tested in trial NCT01680900?
The interventions under investigation include: vilazodone (DRUG), placebo capsules (DRUG).
Who is sponsoring clinical trial NCT01680900?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01680900 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hot Flushes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.